Pfizer-BioNTech claimed on Wednesday that the United Kingdom has allowed the emergency use of their vaccine for the coronavirus disease 2019 (Covid-19) vaccine.
Latest tests have shown that the Pfizer-BioNTech Covid-19 vaccine is at least 95-percent effective.
Pfizer and BioNTech have already applied to the European Union drugs regulator for emergency authorization of their Covid-19 vaccine, the pharmaceutical companies announced on Tuesday.
The formal application, submitted to the European Medicines Agency (EMA) on Monday, came after final results showed the vaccine candidate developed by the companies was 94- percent effective in preventing infections.
The vaccine candidate BNT162b2, developed by Turkish-German scientist Ugur Sahin’s BioNTech company, can also treat adults aged 65 and over, according to the results of Phase 3 clinical study.
Sahin expressed hope on Tuesday that they would soon be able to ship the Covid-19 vaccine doses worldwide after receiving the authorizations.
“As a company located in the heart of Europe, today’s milestone is important to us as we continue to seek to enable a worldwide supply upon potential approval of BNT162b2,” Sahin said in a statement.
Last month, BioNTech and Pfizer submitted a request to the US Food and Drug Administration for emergency use authorization of their vaccine candidate. SOVEREIGNPH